Bank of New York Mellon
NRIX icon

Bank of New York Mellon’s Nurix Therapeutics NRIX Stock Holding History

Bank of New York Mellon’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.61M Sell
272,640
-22,705
-8% -$387K ﹤0.01% 2275
2026
Q1 		$4.58M Buy
295,345
+7,202
+2% +$119K ﹤0.01% 2365
2025
Q4 		$5.47M Buy
288,143
+59,385
+26% +$853K ﹤0.01% 2272
2025
Q3 		$2.11M Buy
228,758
+4,633
+2% +$48.1K ﹤0.01% 2776
2025
Q2 		$2.55M Buy
224,125
+19,047
+9% +$206K ﹤0.01% 2630
2025
Q1 		$2.44M Buy
205,078
+14,173
+7% +$237K ﹤0.01% 2593
2024
Q4 		$3.6M Buy
190,905
+15,639
+9% +$358K ﹤0.01% 2464
2024
Q3 		$3.94M Sell
175,266
-33,870
-16% -$767K ﹤0.01% 2412
2024
Q2 		$4.36M Buy
209,136
+49,918
+31% +$777K ﹤0.01% 2398
2024
Q1 		$2.34M Sell
159,218
-13,859
-8% -$149K ﹤0.01% 2687
2023
Q4 		$1.79M Buy
173,077
+2,791
+2% +$19.1K ﹤0.01% 2894
2023
Q3 		$1.34M Buy
170,286
+4,816
+3% +$44K ﹤0.01% 3010
2023
Q2 		$1.65M Buy
165,470
+7,161
+5% +$73K ﹤0.01% 2939
2023
Q1 		$1.41M Sell
158,309
-2,235
-1% -$23.3K ﹤0.01% 2989
2022
Q4 		$1.76M Buy
160,544
+1,784
+1% +$21.5K ﹤0.01% 2919
2022
Q3 		$2.07M Buy
158,760
+23,057
+17% +$365K ﹤0.01% 2829
2022
Q2 		$1.72M Buy
135,703
+31,581
+30% +$358K ﹤0.01% 2916
2022
Q1 		$1.46M Buy
104,122
+104
+0.1% +$1.85K ﹤0.01% 3098
2021
Q4 		$3.01M Buy
104,018
+5,731
+6% +$174K ﹤0.01% 2748
2021
Q3 		$2.94M Buy
98,287
+20,260
+26% +$625K ﹤0.01% 2777
2021
Q2 		$2.07M Buy
78,027
+11,329
+17% +$333K ﹤0.01% 2963
2021
Q1 		$2.07M Buy
66,698
+22,324
+50% +$845K ﹤0.01% 2903
2020
Q4 		$1.46M Buy
44,374
+16,482
+59% +$546K ﹤0.01% 3025
2020
Q3 		$974K Buy
+27,892
New +$703K ﹤0.01% 3140

Other funds holding NRIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

Bank of New York Mellon's NRIX Position: Q2 2026 in Review

Bank of New York Mellon reduced its Nurix Therapeutics (NRIX) stake by 7.7% in Q2 2026, selling an estimated $387K and leaving 272,640 shares worth $6.61M. The position accounts for ﹤0.01% of the portfolio, ranked #2275.

Bank of New York Mellon first reported a position in NRIX in Q3 2020 and has held it in 24 quarters since. 91 funds tracked by Wall St. Rank hold NRIX as of Q2 2026.

  • Bank of New York Mellon held 272,640 shares of Nurix Therapeutics worth $6.61M as of Q2 2026.
  • Bank of New York Mellon sold 22,705 Nurix Therapeutics shares in Q2 2026, an estimated $387K.
  • Nurix Therapeutics made up ﹤0.01% of Bank of New York Mellon's portfolio in Q2 2026, its #2275 holding.
  • Bank of New York Mellon first reported a position in Nurix Therapeutics in Q3 2020 and has held it in 24 quarters since.
  • 91 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q2 2026.

Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.